Sodium valproate in the treatment of cerebellar disorders.

Article date: 1979/11/1

PubMed ID: 120757

Journal name: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (ISSN: 0317-1671)


Because of the high concentrations of gamma-aminobutyric acid (GABA) in the cerebellar cortex and nuclei, an attempt was made to enhance GABAergic transmission in patients with cerebellar disease. Maximum tolerated doses of sodium valproate, a drug which inhibits the degradation of GABA, failed to influence cerebellar deficits in a double blind crossover study on six patients.

This document is available from: http://directlinks.cc/files/muscimol/120757.pdf

Author List: Neophytides A N, Teychenne P F, Pfeiffer R F, Calne D B

Publication Types: Clinical Trial; Controlled Clinical Trial; Journal Article

Substances mentioned in the article: Muscimol; Clonazepam; Valproic Acid;

Mesh terms: Cerebellar Diseases/drug therapy; Clonazepam/therapeutic use; Double-Blind Method; Female; Humans; Male; Muscimol/therapeutic use; Valproic Acid/administration & dosage;

120757.txt · Last modified: 2018/11/22 21:16 (external edit)